In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Showing 1 to 50 of 126

TitleTypeExpected publication date
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]Technology appraisal guidanceTBC
Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer TSID 12065Technology appraisal guidanceTBC
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer ID6339Technology appraisal guidance
Advanced breast cancer: diagnosis and management (Partial update)NICE guidelineTBC
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]Technology appraisal guidance
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256Technology appraisal guidance
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]Technology appraisal guidanceTBC
Artificial intelligence (AI) technologies for assessing and triaging skin lesions within the urgent suspected skin cancer pathwayHealth technology evaluation
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701Technology appraisal guidanceTBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]Technology appraisal guidanceTBC
Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]Technology appraisal guidanceTBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]Technology appraisal guidanceTBC
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (MA review of TA823) [ID6324]Technology appraisal guidance
Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]Technology appraisal guidanceTBC
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]Technology appraisal guidanceTBC
Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]Technology appraisal guidanceTBC
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]Technology appraisal guidanceTBC
Avelumab for previously treated platinum-resistant ovarian cancer ID1497Technology appraisal guidanceTBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]Technology appraisal guidanceTBC
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]Technology appraisal guidance
Breast cancer guidelinesNICE guidelineTBC
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]Technology appraisal guidance
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]Technology appraisal guidanceTBC
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]Technology appraisal guidanceTBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]Technology appraisal guidance
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]Technology appraisal guidanceTBC
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]Technology appraisal guidanceTBC
COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessmentHealth technology evaluationTBC
Colon cancer (adjuvant) - irinotecan [ID379]Technology appraisal guidanceTBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]Technology appraisal guidanceTBC
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (MA review of TA529) [ID6289]Technology appraisal guidance
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer ID6452Technology appraisal guidanceTBC
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]Technology appraisal guidanceTBC
Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]Technology appraisal guidance
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]Technology appraisal guidanceTBC
Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency ID6415Technology appraisal guidance
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]NICE guidelineTBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]Technology appraisal guidanceTBC
Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation ID5073Technology appraisal guidance
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer [ID6220]Technology appraisal guidanceTBC
Durvalumab with concurrent chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]Technology appraisal guidanceTBC
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317Technology appraisal guidance
Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)NICE guideline
Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]Technology appraisal guidanceTBC
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]Technology appraisal guidance
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]Technology appraisal guidance
Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]Technology appraisal guidance
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]Technology appraisal guidance
Fruquintinib for previously treated metastatic colorectal cancer ID6274Technology appraisal guidance
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All